Sources

4 Total Sources

Georgia Hospitals Test FDA-Approved Daraxonrasib for Metastatic Pancreatic Cancer, Doubling Survival to 13 Months

The Atlanta Journal Constitution8h ago
Georgia Hospitals Test FDA-Approved Daraxonrasib for Metastatic Pancreatic Cancer
Oncology News Central8h ago
Daraxonrasib Doubles Survival in Pancreatic Cancer at ASCO 2026: A Game-Changer
YouTube8h ago
The Emerging Role of RAS Inhibitors in Pancreatic Cancer
OncLive8h ago
Dr Garrido-Laguna on the Safety and Efficacy of Daraxonrasib in KRAS-Mutated PDAC | OncLive